Kenneth H Mayer1, Gita Ramjee. 1. aThe Fenway Institute/Fenway Health, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard T.H. Chan School of Public Health, Boston, Massachusetts USA bHIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa cDepartment of Epidemiology and Population Health, London School of Hygeine and Tropical Medicine, London, UK.
Abstract
PURPOSE OF REVIEW: This review was designed to evaluate the progress in studies of the use of oral and topical antiretroviral (ARV) medication for primary HIV prevention. RECENT FINDINGS: Nonhuman primate data have suggested that the administration of ARV medication before or after retroviral exposure can protect against the establishment of chronic infection. Over the past two decades, observational studies have demonstrated the safety of ARV agents for postexposure prophylaxis and more recent efficacy studies have demonstrated that tenofovir with or without emtricitabine can protect against HIV when used as preexposure prophylaxis (PrEP). Efficacy studies have been conducted in diverse populations, including men and transgender women who have sex with men, young African heterosexuals, and injection drug users. Three studies in African women evaluating oral and topical tenofovir-based regimens did not demonstrate efficacy, in large part because of suboptimal medication adherence. Further research is underway to determine the optimal ways to provide chemoprophylaxis, the optimal medications, and dosing regimens. SUMMARY: PrEP can be effective in decreasing HIV transmission to at-risk uninfected persons, but further research is needed to determine the optimal modes of delivery.
PURPOSE OF REVIEW: This review was designed to evaluate the progress in studies of the use of oral and topical antiretroviral (ARV) medication for primary HIV prevention. RECENT FINDINGS: Nonhuman primate data have suggested that the administration of ARV medication before or after retroviral exposure can protect against the establishment of chronic infection. Over the past two decades, observational studies have demonstrated the safety of ARV agents for postexposure prophylaxis and more recent efficacy studies have demonstrated that tenofovir with or without emtricitabine can protect against HIV when used as preexposure prophylaxis (PrEP). Efficacy studies have been conducted in diverse populations, including men and transgender women who have sex with men, young African heterosexuals, and injection drug users. Three studies in African women evaluating oral and topical tenofovir-based regimens did not demonstrate efficacy, in large part because of suboptimal medication adherence. Further research is underway to determine the optimal ways to provide chemoprophylaxis, the optimal medications, and dosing regimens. SUMMARY:PrEP can be effective in decreasing HIV transmission to at-risk uninfected persons, but further research is needed to determine the optimal modes of delivery.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Myron S Cohen; M Kumi Smith; Kathryn E Muessig; Timothy B Hallett; Kimberly A Powers; Angela D Kashuba Journal: Lancet Date: 2013-10-23 Impact factor: 79.321
Authors: Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller Journal: Curr HIV/AIDS Rep Date: 2018-06 Impact factor: 5.071
Authors: Peter R Chai; Luis M Pereira; Guruprasad D Jambaulikar; Adam W Carrico; Conall O'Cleirigh; Kenneth H Mayer; Edward W Boyer Journal: AIDS Res Hum Retroviruses Date: 2019-03-13 Impact factor: 2.205
Authors: Sarah K Calabrese; Kristen Underhill; Valerie A Earnshaw; Nathan B Hansen; Trace S Kershaw; Manya Magnus; Douglas S Krakower; Kenneth H Mayer; Joseph R Betancourt; John F Dovidio Journal: AIDS Behav Date: 2016-07
Authors: Sarah K Calabrese; Manya Magnus; Kenneth H Mayer; Douglas S Krakower; Adam I Eldahan; Lauren A Gaston Hawkins; Kristen Underhill; Nathan B Hansen; Trace S Kershaw; Joseph R Betancourt; John F Dovidio Journal: AIDS Patient Care STDS Date: 2017-04 Impact factor: 5.078
Authors: Martina Kovarova; Michael D Swanson; Rosa I Sanchez; Caroline E Baker; Justin Steve; Rae Ann Spagnuolo; Bonnie J Howell; Daria J Hazuda; J Victor Garcia Journal: J Antimicrob Chemother Date: 2016-03-21 Impact factor: 5.790
Authors: Sarah K Calabrese; Manya Magnus; Kenneth H Mayer; Douglas S Krakower; Adam I Eldahan; Lauren A Gaston Hawkins; Nathan B Hansen; Trace S Kershaw; Kristen Underhill; Joseph R Betancourt; John F Dovidio Journal: PLoS One Date: 2016-06-15 Impact factor: 3.240